A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD7 in Patients With Refractory or Relapsed T Cell Malignancies

Study Summary

This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.

Interventions

Study Locations

Facility	City	State	Country
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)	Hefei	Anhui	China
Fundamenta Therapeutice Co.,Ltd	Suzhou	Jiangsu	China

Official Trial Information

View on ClinicalTrials.gov